fda glp-1 compounding enforcement news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA cracks down on 'misleading'
Description
You may have heard the buzz about injectable medicines that many people are now using to help them lose weight and wondered if one of them could be right for
Learn how they work, how they differ, whether they can be combined, and what side effects to watch for.

Among the individual GLP-1RAs assessed, the largest reductions in CV risk, HbA1c, and weight outcomes were observed with combination therapy with SGLT2i and once weekly semaglutide for T2D
Not Applied to the Mouth or LipsThis product is not used on the mouth, does not close the lips, and is not intended for breathing modification.

This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr
Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity